Trial Profile
An Open-label, Phase I Trial to Determine the Maximum-tolerated Dose and Investigate Safety, Pharmacokinetics and Efficacy of BI 905677 Administered Intravenously in Patients With Advanced Solid Tumours
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 07 Mar 2024
Price :
$35
*
At a glance
- Drugs BI 905677 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Boehringer Ingelheim
- 16 Mar 2023 Status changed from completed to discontinued.
- 04 Aug 2022 Status changed from active, no longer recruiting to completed.
- 12 Jul 2022 Planned End Date changed from 1 Nov 2022 to 27 Jul 2022.